恒瑞医药：子公司SHR-A2102及阿得贝利单抗注射液获临床试验批准

Core Viewpoint - Heng Rui Medicine announced that its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd. have received approval from the National Medical Products Administration for clinical trials of SHR-A2102 and Adebeli monoclonal antibody injection [1] Group 1 - SHR-A2102 is a targeted antibody-drug conjugate (ADC) developed independently by the company, targeting Nectin-4 [1] - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by the company [1] - The clinical trials for these drugs will commence shortly [1]